CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 243 enrolled
Drug / intervention
Influenza Vaccine GSK1247446A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00545025
NCT00545025Phase 2Completed
CompareCT.gov

Safety and Immunogenicity of a Second Vaccination With GSK Biologicals' Influenza Vaccine GSK1247446A in Subjects 18-60 Years Previously Vaccinated in Study 108656

GlaxoSmithKline·interventional·Posted Oct 16, 2007·Updated Jun 26, 2019

In Brief

A Phase 2 clinical trial evaluating Influenza Vaccine GSK1247446A and Fluarix™ for Influenza and Influenza, Human. Completed, enrolled 243 participants across 1 site.

Detailed Summary

The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Influenza, Human
CountriesBelgium
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 16, 2007
Enrollment StartOct 15, 2007
Primary CompletionDec 12, 2007
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.7 years ago

Interventions

Influenza Vaccine GSK1247446Abiological

Single dose, Intramuscular injection

Fluarix™biological

Single dose, Intramuscular injection